Bristol-Myers Squibb (BMY)’s Solid Growth Potential in 2017

Bristol-Myers Squibb (NYSE:BMY) is down over 4% year-to-date, but the stock is looking in a good shape for future gains. The company has a promising pipeline, and outperforming drugs, including cancer treatments Opdivo, Yervoy, Sprycel and Empliciti. Bristol’s autoimmune drug Orencia is also returning solid growth.

Unlike other US pharmaceutical companies, Bristol-Myers Squibb (NYSE:BMY) is targeting China, one of the largest markets. The company will launch to Hepatitis C drugs in three Chinese provinces this quarter. If sales of these drugs take off, the stock will get a major boost. Almost all of the top performing drugs patents of Bristol-Myers Squibb (NYSE:BMY) are valid till 2027, so the company has a lot of time to work on alternatives and pipeline.

Over the current book year the total revenue will be 20,45 billion USD (consensus estimates). This is slightly more than 2016's revenue of 19,43 billion USD.

Historical revenues and results Bristol-Myers Squibb plus estimates 2017

The analysts expect for 2017 a net profit of 4,93 billion USD. For this year the consensus of Bristol-Myers Squibb 's result per share is a profit of 2,97 USD. The price/earnings-ratio is then 19,1.

Per share the analysts expect a dividend of 1,58 USD per share. The dividend yield is then 2,79 percent. The average dividend yield of the pharmaceutical companies equals a poor 1,28 percent.

Historical stock prices Bristol-Myers Squibb past 10 years

On Friday the stock closed at 56,73 USD.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.